GRAL vs PSNL
GRAL: GRAIL is developing Galleri, a blood-based multi-cancer early detection test designed to detect many types of cancer from a single draw and pinpoint the tissue of origin, pending FDA approval. PSNL: A genomic testing company enabling precision oncology through ultra-sensitive liquid biopsy and tumor sequencing to detect cancer recurrence and guide personalized treatment decisions.
Side-by-side fundamentals
| Metric | GRAL | PSNL | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $66.77 | $12.28 | |
| Market cap as of 2026-07-31 | $3.1B | $1.3B | |
| Net margin as of 2026-07-31 | -253.2% | -148.1% | PSNL higher |
| Gross margin as of 2026-07-31 | +49.3% | +13.7% | GRAL higher |
| Operating margin as of 2026-07-31 | -348.7% | -158.9% | PSNL higher |
| ROE as of 2026-07-31 | -16.4% | -43.5% | GRAL higher |
| ROA as of 2026-07-31 | -14.3% | -32.9% | GRAL higher |
| Debt / equity as of 2026-07-31 | 0.00 | 0.00 | GRAL lower |
| Revenue growth (YoY) as of 2026-07-31 | +19.4% | -24.7% | GRAL higher |
| Revenue CAGR (3y) SEC XBRL | +25.7% | +2.3% | GRAL higher |
| Beta as of 2026-07-31 | 2.21 | 2.18 | |
| 1-year return as of 2026-07-27 close | +65.7% | +119.7% | PSNL higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.